German healthcare group Fresenius has lifted its full-year profit outlook for the second time in 2025, following a third quarter that came in ahead of market expectations. The company now expects its earnings-before-interest-and-taxes (EBIT) margin to land above 11.5% for the full year, up from its previous guidance of around 11.5%. It also nudged its 2026 constant-currency core earnings-per-share (EPS) growth toward the upper end of its 10%–15% range.
The update, reported by Reuters on Wednesday, reflects stronger-than-expected performance at two of its key businesses: Fresenius Kabi, which makes medicines and nutrition products, and Helios, its hospital operator. The company said efficiency measures and improving profitability in Germany and Spain were behind the better results.
What drove the beat
In the third quarter, Fresenius reported EBIT before special items of €638 million, ahead of the €618.5 million consensus compiled by research firm Vara Research. Fresenius Kabi contributed €391 million of that total, while Helios added €293 million.
These numbers matter because they show the company’s turnaround plan, led by CEO Michael Sen, is gaining traction. Sen has focused on lifting profitability and reducing debt since taking the helm, and the latest results suggest those efforts are paying off.
The company is also working to distance itself from its former dialysis unit, Fresenius Medical Care, in which it still holds about a 25% stake. That business recently cut its operating income outlook after another decline in US treatment volumes, a reminder that not all parts of the Fresenius empire are firing on all cylinders.
Why the guidance raise matters
When a company raises guidance twice in a single year, investors tend to treat it as more than just a one-off good quarter. It signals that management has growing confidence in the underlying momentum, and it often prompts analysts to update their models for future years.
With Fresenius pointing to an EBIT margin above 11.5% and 2026 core EPS growth at the upper end of its 10%–15% range, broker forecasts for next year and beyond are likely to creep higher in the days and weeks after the results. That can have a knock-on effect on how the stock is valued.
If the share price doesn’t immediately move in step with those higher earnings expectations, the stock can look cheaper on a forward price-to-earnings (P/E) basis. That, in turn, can later support a re-rating of the shares. So the bigger tell from here is the pace of consensus EPS upgrades, not just the size of the Q3 beat.
What it means for investors
For everyday investors, the key takeaway is that Fresenius is delivering on its turnaround promises. The company’s focus on efficiency and profitability is showing up in the numbers, and the raised guidance suggests management sees more upside ahead.
That said, it’s worth keeping an eye on the broader picture. Fresenius operates in a sector where pricing pressure and regulatory changes can hit margins, and its remaining stake in Fresenius Medical Care adds an element of uncertainty. The dialysis unit’s recent struggles highlight that not all parts of the business are improving at the same pace.
Investors will likely watch next for how analysts adjust their forecasts and whether the company can sustain this momentum into 2026. The raised guidance is a positive signal, but it also raises the bar for future performance.
For context, other European companies have also been updating their outlooks recently. For instance, Vopak raised its 2026 cash flow target on strong storage demand, and Continental lifted its 2026 margin outlook as premium tire demand offset higher costs. These moves, like Fresenius’s, reflect a broader theme of companies expressing confidence in their ability to grow profits despite a mixed macroeconomic backdrop.
Fresenius’s update also comes as other healthcare names report mixed results. Novo Nordisk beat Q3 expectations but kept its 2026 growth guidance tight, showing that even strong performers are being cautious about the future.
For now, Fresenius’s raised guidance is a clear sign that its turnaround is on track. Whether that translates into sustained share price gains will depend on how well the company executes in the coming quarters and whether analysts’ upgraded forecasts hold up.
